lncRNA HOTTIP Recruits EZH2 to Inhibit PTEN Expression and Participates in IM Resistance in Chronic Myeloid Leukemia

Exosomal Long Non-coding RNA HOTTIP Increases Resistance of Colorectal Cancer Cells to Mitomycin via Impairing MiR-214-Mediated Degradation of KPNA3

(2021) Xijuan Chen et al.   Frontiers in Cell and Developmental Biology

Third-line therapy for chronic myeloid leukemia: current status and future directions

(2021) Jorge Cortes et al.   Journal of Hematology & Oncology

Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance

(2021) Raquel Alves et al.   Cancers

Response and Resistance to BCR-ABL1-Targeted Therapies

(2020) Theodore P. Braun et al.   CANCER CELL

HOTTIP Predicts Poor Survival in Gastric Cancer Patients and Contributes to Cisplatin Resistance by Sponging miR-216a-5p

(2020) Rui Zhao et al.   Frontiers in Cell and Developmental Biology

The HOTTIP (HOXA transcript at the distal tip) lncRNA: Review of oncogenic roles in human

(2020) Soudeh Ghafouri-Fard et al.   BIOMEDICINE & PHARMACOTHERAPY

EZH2 in Myeloid Malignancies

(2020) Jenny Rinke et al.   Cells

Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

(2020) Michael W. Deininger et al.   Journal of the National Comprehensive Cancer Network

Chronic myeloid leukemia stem cells

(2019) Mohammad Houshmand et al.   LEUKEMIA

BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia

(2019) Federica Loscocco et al.   Frontiers in Oncology

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

(2018) Antoine Italiano et al.   LANCET ONCOLOGY

Targeting glioma stem cells through combined BMI1 and EZH2 inhibition

(2017) Xun Jin et al.   NATURE MEDICINE

The cancer epigenome: Concepts, challenges, and therapeutic opportunities

(2017) Mark A. Dawson   SCIENCE

BCR/ABL increases EZH2 levels which regulates XIAP expression via miRNA-219 in chronic myeloid leukemia cells

(2016) Chie Nishioka et al.   LEUKEMIA RESEARCH

Targeting EZH2 in cancer

(2016) Kimberly H Kim et al.   NATURE MEDICINE

Unique features of long non-coding RNA biogenesis and function

(2016) Jeffrey J. Quinn et al.   NATURE REVIEWS GENETICS

Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition

(2016) M. T. Scott et al.   Cancer Discovery

Chronic Myelogenous Leukemia- Initiating Cells Require Polycomb Group Protein EZH2

(2016) H. Xie et al.   Cancer Discovery

DNMT3A in Leukemia

(2016) Lorenzo Brunetti et al.   Cold Spring Harbor Perspectives in Medicine

EZH2 expands breast stem cells through activation of NOTCH1 signaling

(2014) M. E. Gonzalez et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

(2013) M. Baccarani et al.   BLOOD

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

(2013)   BLOOD

EZH2 Is Required for Breast and Pancreatic Cancer Stem Cell Maintenance and Can Be Used as a Functional Cancer Stem Cell Reporter

(2012) Lilian E. van Vlerken et al.   Stem Cells Translational Medicine

Translation of the Philadelphia chromosome into therapy for CML

(2008) B. J. Druker   BLOOD